INTELLIA THERAPEUTICS
Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments. It can positively transform the lives of people living with severe and life-threatening diseases. IIntellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. The company is advancing a broad pipeline toward clinical development, including ex Vivo, and in vivo approaches. Intellia Therapeutics was formed in 2014 and is headquartered in Cambridge, Massachusetts.
INTELLIA THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Medical Therapeutics
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.intelliatx.com
Total Employee:
251+
Status:
Active
Contact:
(857) 285-6200
Email Addresses:
[email protected]
Total Funding:
775 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
2seventy bio
2seventy bio is an immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Chroma Medicine
Chroma Medicine is a new genomic medicine company working on epigenetic editing.
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-02-03 | Rewrite Therapeutics | Rewrite Therapeutics acquired by Intellia Therapeutics | N/A |
Investors List
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - Intellia Therapeutics
Janus Capital Group
Janus Capital Group investment in Series B - Intellia Therapeutics
Sectoral Asset Management
Sectoral Asset Management investment in Series B - Intellia Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Series B - Intellia Therapeutics
Foresite Capital
Foresite Capital investment in Series B - Intellia Therapeutics
Atlas Venture
Atlas Venture investment in Series B - Intellia Therapeutics
OrbiMed
OrbiMed investment in Series B - Intellia Therapeutics
Novartis
Novartis investment in Series B - Intellia Therapeutics
Caribou Biosciences
Caribou Biosciences investment in Series A - Intellia Therapeutics
Novartis
Novartis investment in Series A - Intellia Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-01-26 | Kyverna Therapeutics | Intellia Therapeutics investment in Series B - Kyverna Therapeutics | 85 M USD |
| 2021-10-13 | SparingVision | Intellia Therapeutics investment in Corporate Round - SparingVision | N/A |
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-16 | Orna Therapeutics Expands Leadership Team with Key Executive Hires |
| 2020-04-30 | Intellia Therapeutics Taps Semma’s Lebwohl as Chief Medical Officer |
Official Site Inspections
http://www.intelliatx.com Semrush global rank: 1.26 M Semrush visits lastest month: 23.7 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Intellia Therapeutics"
Intellia Therapeutics - Revolutionize the course of medicine
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.See details»
Intellia Therapeutics - Wikipedia
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causi…See details»
Intellia Therapeutics - Crunchbase Company Profile & Funding
Organization. Intellia Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone …See details»
Intellia Therapeutics, Inc. | LinkedIn
Intellia Therapeutics, Inc. | 60,833 followers on LinkedIn. Developing curative genome editing treatments | Intellia Therapeutics is a leading genome editing company whose mission is to develop ...See details»
Vice President, Investor Relations and Corporate Communications ...
Will act as a Company spokesperson, promoting, enhancing, and projecting the organization's vision, brand and reputation to external stakeholders, with a primary focus on analysts and …See details»
Intellia Therapeutics Announces Anticipated 2025 Milestones and ...
Jan 9, 2025 Learn more at intelliatx.com and follow us @intelliatx. Forward-Looking Statements. ... priorities reflect the Company’s ongoing evolution from a late-stage development company …See details»
Intellia Therapeutics (USA) Funding: $1.5B - medicalstartups.org
Apr 2, 2025 Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool …See details»
SEC Filing - Intellia Therapeutics
In submitting this notice, each issuer named above is: Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, …See details»
Intellia Therapeutics Highlights its Three-Year Strategic Priorities ...
Jan 4, 2024 Board Update: In December, Intellia announced the departure of John Crowley from its board of directors following his appointment as Chief Executive Officer of the Biotechnology …See details»
Intellia Therapeutics, Inc.: Culture | LinkedIn
Intellia Therapeutics, Inc. | 60,190 followers on LinkedIn. Developing curative genome editing treatments | Intellia Therapeutics is a leading genome editing company whose mission is to develop ...See details»
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 ...
Feb 24, 2022 This increase was primarily driven by the advancement of our lead programs, research personnel growth to support these programs and expansion of the development …See details»
Intellia Therapeutics Announces Two Upcoming Investor Events in ...
Nov 1, 2024 Learn more at intelliatx.com and follow us @intelliatx. Intellia Contacts: Investors: Lina Li Senior Director, Investor Relations and Corporate Communications …See details»
Intellia Therapeutics Highlights its Three-Year Strategic Priorities ...
Jan 4, 2024 NTLA-2001 for ATTR Amyloidosis: Dose the first patient in MAGNITUDE trial of NTLA-2001 for the treatment of ATTR-CM in Q1 2024. Continue to open new sites and enroll …See details»
Intellia Therapeutics (@intelliatx) • Instagram photos and videos
See our website for details: www.intelliatx.com #CRISPR #GeneEditing. We’ve arrived at the @american_heart Scientific Sessions! #aha2024 #oneintellia. Intellia is gearing up for the …See details»
Insights, Analytics and Forecasting Lead - Intellia Therapeutics
How You Will Achieve More With Intellia: The Insights, Analytics and Forecasting Lead will play a critical role in the launch and success of Intellia’s commercial organization. Reporting to the …See details»
intelliatx.org
Intelliatx.orgSee details»
ONE Intellia - Intellia Therapeutics
At Intellia, individuals are celebrated and supported. We work together as ONE: a culmination of the qualities and strengths that come from our differences, including race, gender, age, …See details»
Intellia Therapeutics to Hold Conference Call to Discuss Fourth …
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing …See details»
CEO reorganizes Intel with new CTO and AI lead - Tom's Hardware
4 days ago Intel's Lip-Bu Tan has overhauled leadership by naming Sachin Katti as CTO and AI chief, flattening the structure, and taking direct control of key technology developments.See details»
Scientific Publications & Presentations - Intellia Therapeutics
American Academy of Allergy, Asthma & Immunology and World Allergy Organization Joint Congress. attr presentation. Nov 16, 2024. Nexiguran Ziclumeran (nex-z, Also Known as …See details»